Details of the Drug
General Information of Drug (ID: DMOT1LQ)
Drug Name |
2-Hydrazino-3-methyl-4(3H)-quinazolinone
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
2-hydrazino-3-methylquinazolin-4(3H)-one; 61507-80-0; 2-Hydrazino-3-methyl-3H-quinazolin-4-one; 2-Hydrazino-3-methyl-4(3H)-quinazolinone; NSC657432; CHEMBL503552; 2-hydrazinyl-3-methylquinazolin-4(3H)-one; 2-hydrazinyl-3-methylquinazolin-4-one; BAS 00718750; 4(3H)-Quinazolinone,2-hydrazinyl-3-methyl-; 2-hydrazinyl-3-methyl-3,4-dihydroquinazolin-4-one; 2-hydrazino-3-methyl-3-hydroquinazolin-4-one; AC1Q6DRE; AC1L8CIY; AC1Q3XQM; 2-Hydrazino-3-methyl-3 H -quinazolin-4-one; Oprea1_318278; Oprea1_401830; MLS000713036; CTK5B3345
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 190.2 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 0 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 1 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 2 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 3 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||